FDA Cites Facilities in China, Japan, and India Post author:Sam Post published:February 14, 2017 Post category:Drug Industry Daily The FDA issued warning letters to four overseas manufacturers over GMP and other failures. Source: Drug Industry Daily You Might Also Like Eiger’s Peginterferon Lambda Cuts COVID-19 Hospitalizations in Half, Trial Shows February 8, 2023 FDA Invites Meeting Requests for Pilot Program to Spur Clinical Trial Innovation August 29, 2018 Legislative Update — Week of May 1, 2023 May 2, 2023